mir-31
mir-31 | |
---|---|
Identifiers | |
Symbol | mir-31 |
Rfam | RF00661 |
miRBase family | MIPF0000064 |
Other data | |
RNA type | microRNA |
Domain(s) | Eukaryota |
PDB structures | PDBe |
miR-31 has been characterised as a
Functions
mir-31 has been linked to Duchenne muscular dystrophy − a genetic disorder characterised by a lack of the protein dystrophin − as a potential therapeutic target. Duchenne muscular dystrophy is caused by mutations arising in the dystrophin gene, which impair the translation of dystrophin through the formation of premature termination codons.[5]
miR-31 overexpression is more abundant in human Duchenne muscular dystrophy than in healthy controls, with levels remaining high only in Duchenne muscular dystrophy myoblasts. miR-31 levels in healthy controls are instead decreased with the onset of cell differentiation. miR-31 is part of the circuit controlling late muscle differentiation by repression of dystrophin synthesis, and its expression is localised specifically to regenerating myoblasts of dystrophic muscles.[6] miR-31 is believed to repress the expression of dystrophin by antisense binding of the dystrophin mRNA 3′ untranslated region, and in this way it is thought that miR-31 manipulation could aid treatment for Duchenne muscular dystrophy.
Applications
In serous ovarian cancer, miR-31 is frequently deleted and is the most underexpressed microRNA in this cancer type. It has been shown to affect the levels of gene transcription factor p53, responsible for encoding the tumour suppressor protein
References
- PMID 20346098.
- PMID 19524507.
- ^
Fong LY, Taccioli C, Jing R, Smalley KJ, Alder H, Jiang Y, Fadda P, Farber JL, Croce CM (2016). "MicroRNA dysregulation and esophageal cancer development depend on the extent of zinc dietary deficiency". Oncotarget. 7 (10): 10723–38. PMID 26918602.
- PMID 21406558.
- PMID 21212803.
- PMID 21212803.
- S2CID 21836130.
- PMID 20179198.
- S2CID 22851497.
- PMID 26150916.
- PMID 26286729.
- PMID 19408243.
- PMID 21149603.
Further reading
- Olaru AV, Selaru FM, Mori Y, Vazquez C, David S, Paun B, Cheng Y, Jin Z, Yang J, Agarwal R, Abraham JM, Dassopoulos T, Harris M, Bayless TM, Kwon J, Harpaz N, Livak F, Meltzer SJ (2010). "Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation". Inflamm Bowel Dis. 17 (1): 221–231. PMID 20848542.
- Cottonham CL, Kaneko S, Xu L (2010). "miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells". J Biol Chem. 285 (46): 35293–35302. PMID 20826792.
- Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA (2010). "Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis". Cancer Res. 70 (12): 5147–5154. PMID 20530680.
- Valastyan S, Weinberg RA (2010). "miR-31: A crucial overseer of tumor metastasis and other emerging roles". Cell Cycle. 9 (11): 2124–2129. PMID 20505365.
- Pedrioli DM, Karpanen T, Dabouras V, Jurisic G, van de Hoek G, Shin JW, Marino D, Kälin RE, Leidel S, Cinelli P, Schulte-Merker S, Brändli AW, Detmar M (2010). "miR-31 functions as a negative regulator of lymphatic vascular lineage-specific differentiation in vitro and vascular development in vivo" (PDF). Mol Cell Biol. 30 (14): 3620–3634. PMID 20479124.
- Ivanov SV, Goparaju CM, Lopez P, Zavadil J, Toren-Haritan G, Rosenwald S, Hoshen M, Chajut A, Cohen D, Pass HI (2010). "Pro-tumorigenic effects of miR-31 loss in mesothelioma". J Biol Chem. 285 (30): 22809–22817. PMID 20463022.
External links